ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

disitamab vedotin

Also written as “RC48-ADC”, “Disitamab Vedotin” and “Disitamab Vedotin Injection”.

In Pfizer’s pipeline, HER2-directed antibody-drug conjugate. Its studies are mostly in Stomach Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3 companies.

Drug pageDisitamab vedotin: every studyAll 117 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 8, 201836 company-led studies, 28 open or runningAcquisition: Pfizer acquired Seagen, Dec 2023Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen3022 open or runningphase 3since Apr 8, 2018Aug 20, 2016Dec 2026phase 3 · NCT06221748
Pfizerits history only55 open or runningphase 3since Jun 9, 2023Apr 19, 2021Dec 11, 2026phase 2 · NCT04879329
Jiangsu HengRui Medicineits history only11 open or runningphase 2since Apr 26, 2024Apr 26, 2024Dec 31, 2031phase 2 · NCT06417554
  • Named in Pfizer’s own pipeline as disitamab vedotin PF-08046051, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Merck.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and studies of RemeGen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 14 earlier studies, Aug 20, 2016 to Nov 15, 2021.

  1. Dec 9, 2018Named disitamab vedotinINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Aug 9, 2021Seagen licensed it from RemeGenLicenseEverywhere outside Asia, and in Japan and Singapore · announced · Seagen and RemeGen (release)
  3. Mar 17, 2022Phase 2 study in Muscle Invasive Bladder CarcinomaNCT05297552 · 40 planned · China
  4. Mar 21, 2022Phase 3 study in Carcinoma, Transitional CellNCT05302284 · 452 planned · China
  5. Feb 16, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05745740 · 26 planned · China
  6. Mar 13, 2023Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05943379 · 85 planned · China
  7. May 8, 2023Phase 1 study in Solid TumorNCT05940896 · 24 planned · China
  8. Jul 1, 2023Phase 3 study in Stomach NeoplasmsNCT05980481 · 201 enrolled · China
  9. Aug 18, 2023Phase 2 study in Solid TumorNCT06016062 · 221 planned · China
  10. Nov 23, 20232 phase 2 studiesNCT06155396, NCT06155383
  11. Dec 3, 2023Phase 2 study in Breast NeoplasmsNCT06178159 · 40 planned · China
  12. Dec 14, 2023Pfizer acquired SeagenAcquisitionWith it the rights Seagen held · completed · Pfizer (release)
  13. Jan 15, 2024Phase 3 study in Stomach NeoplasmsNCT06221748 · 90 planned · China
  14. Jan 17, 20242 phase 2 studiesNCT06227156, NCT06227117
  15. Apr 12, 2024Phase 2 study in High-risk Non-muscle Invasive Bladder CancerNCT06378242 · 24 planned · China
  16. Apr 17, 2025Phase 3 study in Stomach NeoplasmsNCT06944496 · 616 planned · China
  17. Dec 3, 2025Phase 3 study in Stomach NeoplasmsNCT07315750 · 555 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsNCT06221748
  2. Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Transitional CellNCT05302284
  3. Jun 30, 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT06155396
  4. Dec 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05745740

TargetBeta

“HER2-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via the protease-cleavable linker maleimidocaproyl-valine-…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 30 RemeGen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07315750Stomach Neoplasms · China3RecruitingJun 30, 2029555
NCT06944496Stomach Neoplasms · China3Not yet recruitingMay 15, 2028616
NCT06378242High-risk Non-muscle Invasive Bladder Cancer · China2RecruitingMar 15, 202924
NCT06227156Castration-resistant Prostate Cancer · China2RecruitingDec 202540
NCT06227117Breast Neoplasms · China2RecruitingDec 2025120
NCT06221748Stomach Neoplasms · China3RecruitingDec 202690
NCT06178159Breast Neoplasms · China2RecruitingJun 202640
NCT06155396Uterine Cervical Neoplasms · China2RecruitingJun 30, 2027116
NCT06155383Stomach Neoplasms · China2RecruitingJan 31, 202590
NCT06016062Solid Tumor · China2RecruitingDec 31, 2025221
NCT05980481Stomach Neoplasms · China3Active, not recruitingJul 10, 2025201
NCT05940896Solid Tumor · China1RecruitingNov 16, 202424
NCT05943379Non-Muscle Invasive Bladder Neoplasms · China2RecruitingDec 1, 202585
NCT05745740Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingDec 1, 202726
NCT05302284Carcinoma, Transitional Cell · China3RecruitingDec 31, 2026452
NCT05297552Muscle Invasive Bladder Carcinoma · China2RecruitingJun 1, 202440
NCT05135715Melanoma · China2RecruitingDec 30, 202450
NCT04965519Gynecological Malignancy · China2RecruitingOct 2024120
NCT04714190Stomach Neoplasms · China3RecruitingDec 1, 2024351
NCT04400695Breast Neoplasms · China3RecruitingDec 31, 2027366
NCT04329429Biliary Tract Neoplasms · China2Active, not recruitingNov 3, 202357
NCT04311034Carcinoma, Non-Small-Cell Lung · China2CompletedDec 21, 202137
NCT04073602Carcinoma, Transitional Cell · China2CompletedSep 30, 202219
NCT03809013Carcinoma, Transitional Cell · China2CompletedMar 4, 202164
NCT03556345Stomach Neoplasms · China2CompletedJun 1, 2020127
NCT03507166Carcinoma, Transitional Cell · China2CompletedOct 29, 201843
NCT03500380Breast Neoplasms · China3Active, not recruitingJul 31, 2024301
NCT03052634Advanced Breast Cancer · China2CompletedJul 31, 2022112
NCT02881190Solid Tumors · China1CompletedJun 27, 201957
NCT02881138Solid Tumors · China1CompletedApr 30, 202024

How it is read

Names in the registry

  • “RC48-ADC”, 15 entries
  • “disitamab vedotin”, 4 entries
  • “Disitamab Vedotin”, 3 entries
  • “Disitamab Vedotin Injection”, 3 entries
  • “Disitamab vedotin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.